TRPLigDrugConj
TRPV1-targeted ligand-drug conjugates to treat prostate cancer
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0TRPLigDrugConj project word cloud
Explore the words cloud of the TRPLigDrugConj project. It provides you a very rough idea of what is the project "TRPLigDrugConj" about.
Project "TRPLigDrugConj" data sheet
The following table provides information about the project.
| Coordinator |
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Organization address contact info |
| Coordinator Country | Portugal [PT] |
| Total cost | 160˙635 € |
| EC max contribution | 160˙635 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2016 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2017 |
| Duration (year-month-day) | from 2017-03-01 to 2019-05-04 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES | PT (LISBOA) | coordinator | 160˙635.00 |
Map
Project objective
Cancer remains a leading cause of death and morbidity worldwide. Prostate cancer (PC) is among the most frequently diagnosed non-skin cancers. Despite major advances in the understanding of cancer biology and development of candidate therapeutic agents, there is still an urgent need of exploiting innovative chemotypes and disrupting novel signalling pathways. Evidence suggests that targeted therapies may provide an original means of selectively modulating diseased prostate cells. Herein we propose the validation and devlopment of an unprecedented approach to tackle PC, addressing the overexpressed transient receptor potential vanilloid channel V1 (TRPV1) with ligand-drug conjugates. This strategy provides a pioneering technological advance by aiming at the disruption of calcium signalling, while selectively targeting cancer cells for the delivery of cytotoxic payloads. The approach will additionally yield chemical probes for studying TRPV1 biology and for whole-animal optical imaging of TRPV1-overexpressed cancer cells.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
Charlotte Baker, Tiago Rodrigues, Bernardo P. de Almeida, Nuno L. Barbosa-Morais, Gonçalo J.L. Bernardes Natural product–drug conjugates for modulation of TRPV1-expressing tumors published pages: 2531-2536, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2019.03.025 |
Bioorganic & Medicinal Chemistry 27/12 | 2019-10-15 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRPLIGDRUGCONJ" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "TRPLIGDRUGCONJ" are provided by the European Opendata Portal: CORDIS opendata.